Chidamide and anlotinib synergistically inhibit high grade B-cell lymphomas via PI3K/AKT signaling pathway

Chidamide and anlotinib synergistically inhibit high grade B-cell lymphomas via PI3K/AKT signaling pathway

Abstract High-grade B-cell lymphoma with concurrent MYC and BCL2/BCL6 rearrangements (HGBL-DHL) is a challenging disease resistant to front-line immunochemotherapies, which urgently requires novel therapeutic approaches. Herein, combination of chidamide and anlotinib demonstrated potential synergist...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiazhen Lin, Xinguo Zhuang, Shuman Jia, Hui Zhou, Dongmei Qin, Jie Zhou, Yiming Luo, Bing Xu, Jie Zha
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
HGBL-DHL
Chidamide
Anlotinib
Synergy
Combination therapy
PI3K/AKT signaling
Online Access:https://doi.org/10.1038/s41598-025-10334-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-10334-1

Similar Items